Effector proteins of Rapamycin
US6713607B2 · kind B2 · utility
48Cited by
4References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2001 |
| Grant date | Mar 30, 2004 |
| Priority date | — |
| Expiry date | Sep 13, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention comprises novel Rapamycin-FKBP12 binding proteins of mammalian origin for identification, design and synthesis of immunomodulatory, anti-restenosis or anti-tumor agents, as well as fragments of the proteins and the DNA, cDNA, antisense RNA and DNA segments corresponding to the proteins. This invention also comprises methods for isolating the proteins and therapeutic uses related to the proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.